It further identified the plasma EV membrane proteins, CD59 and TSPAN9, as a novel biomarker panel that effectively detected CRC through targeted MS-based quantification of roughly a dozen selected candidate membrane proteins in plasma EV samples from 73 CRC patients and 80 age/sex-matched HCs. This evidence concerns the gene TSPAN9 and colorectal carcinoma.